Trade Summary

1 month ago, Siegall Clay B, serving as Pres, CEO at Immunome Inc. (IMNM), purchased 25,450 shares at $19.67 per share, for a total transaction value of $500,602.00. Following this transaction, Siegall Clay B now holds 690,704 shares of IMNM.

This purchase represents a 4.00% increase in Siegall Clay B's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 31, 2026, 4 days after the trade was made.

Immunome Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.